Study of iptacopan for adults with C3G
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how well iptacopan works for people with C3G, a kidney disease. It aims to see if the treatment is safe and effective, and includes people who have already taken iptacopan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of C3G (a kidney disease), preferably confirmed by a biopsy.
- You are at least 18 years old.
- You have had at least 6 months of medical history before starting this study.
- You are currently taking iptacopan, or you stopped taking it within the last 12 weeks.
- You are not participating in any other interventional clinical trial for C3G.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial looks at how well and how safely iptacopan works over the long term for people with C3G or IC-MPGN. You may be able to join if you already finished a specific earlier study and you’re currently healthy enough for long-term treatment.
This trial tests a medicine called iptacopan for people with paroxysmal nocturnal hemoglobinuria (a rare blood disorder) or C3 glomerulopathy (a kidney disease). It aims to see if the drug is safe and effective for Korean patients.
This trial studies whether iptacopan can improve outcomes and safety for people with C3 glomerulopathy, a kidney disease caused by overactive parts of the immune system. Participants must already be on standard kidney-protecting medicines and meet specific kidney function and urine protein criteria.
This study tracks adults with C3G (a rare kidney disease where the immune system damages the filtering units) who have already received iptacopan (a new medicine) through an early access program in Spain. Researchers want to understand how well this treatment works and its safety in real-world patients.
This study tests if adding iptacopan to standard care can improve kidney health in adults with IgA nephropathy. You may qualify if you have a kidney biopsy confirming IgA nephropathy and your kidney function is stable enough.
This trial tests iptacopan (an add-on medicine) in people with idiopathic immune-complex membranoproliferative glomerulonephritis (IC-MPGN), a kidney disease causing significant protein loss in urine. It aims to improve kidney outcomes and safety when added to standard treatments.
Hear when a new C3 Glomerulopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.